Splenic Epstein-Barr virus–positive inflammatory follicular dendritic cell sarcoma (EBV+IFDCS) is an uncommon neoplasm classified as a low-grade malignant tumor. The entity is characteristically associated with infection by the Epstein-Barr virus, a link that is highlighted in the source report. Because of its rarity and low incidence, EBV+IFDCS of the spleen is not frequently encountered in routine clinical practice; most published accounts appear as single-case reports or small series.
The published article from Zhongguo Yi Xue Ke Xue Yuan Xue Bao (2026) presents one case of splenic EBV+IFDCS and places this single observation in the context of previously reported clinicopathological data. The report is indexed under MeSH terms that emphasize dendritic cell sarcoma virology and splenic neoplasms, underscoring its focus on the intersection of morphology and viral association.
According to the source, the majority of patients with splenic EBV+IFDCS are asymptomatic. Lesions are often identified incidentally during routine physical examinations or imaging studies performed for unrelated reasons. When symptoms do occur, they are non-specific and most commonly relate to the abdomen: the source notes that a minority of patients may experience abdominal distension or abdominal pain.
These non-specific presentations contribute to diagnostic ambiguity. The absence of characteristic systemic or constitutional signs means that clinicians may not suspect EBV+IFDCS based on clinical features alone. The report therefore emphasizes the importance of maintaining a broad differential diagnosis when a splenic mass is detected.
Early diagnosis of splenic EBV+IFDCS is challenging because there are no distinctive clinical manifestations that reliably distinguish it from other splenic lesions. Imaging and clinical assessment commonly identify a splenic mass but cannot definitively classify the lesion as EBV+IFDCS. The source explicitly states that the lack of specific clinical manifestations complicates prompt recognition.
Given these limitations, reliance on clinical presentation or imaging alone may delay definitive diagnosis. The rarity of the tumor further reduces clinician familiarity, making awareness and suspicion important for appropriate diagnostic work-up when a splenic mass is encountered.
The source identifies pathological examination as the gold standard for diagnosis of splenic EBV+IFDCS. Histopathologic evaluation, often supplemented by ancillary testing to demonstrate association with Epstein-Barr virus, is central to confirming the diagnosis. This typically involves microscopic assessment of morphology and directed studies for viral markers, although the abstract does not enumerate the specific histologic features or laboratory methods used in the reported case.
Because the abstract does not provide the detailed pathological findings, immunophenotype, or EBV detection method from the reported case, those specifics cannot be summarized here. The article's emphasis, however, is clear: definitive diagnosis rests on tissue examination and demonstration of EBV association.
The article reports one case of splenic EBV+IFDCS and discusses its clinicopathological features in the context of related literature. Beyond stating that a single case was reviewed and that a literature discussion accompanies it, the accessible abstract does not provide detailed clinical or pathological data for the patient, such as demographics, presenting signs beyond the general possibilities, imaging characteristics, surgical or therapeutic interventions, specific histologic descriptors, EBV test details, or outcomes.
Consequently, this summary is limited to the overarching points presented in the abstract: the tumor’s rarity, its typical asymptomatic nature, the potential for non-specific abdominal symptoms in a minority of patients, the diagnostic challenge posed by non-specific clinical features, and the role of pathology as the diagnostic standard. Any additional case-level or follow-up details reported in the full article were not available in the abstract and therefore are not included here.
Consider EBV+IFDCS in the differential diagnosis of splenic masses, particularly when routine evaluation uncovers an indeterminate splenic lesion.
Recognize that most patients may be asymptomatic and that when present, symptoms tend to be non-specific (e.g., abdominal pain or distension), limiting clinical diagnostic specificity.
Arrange for histopathological assessment of splenic tissue when feasible, as pathological examination with demonstration of EBV association is essential to establish the diagnosis.
Be aware that the published literature on splenic EBV+IFDCS is limited and often comprises case reports and small series; the source report contributes one additional case and a literature discussion to this body of evidence.
The abstract does not provide detailed case-level data such as imaging findings, immunohistochemical profile, EBV detection method, treatment approach, or patient outcome; clinicians seeking these specifics should consult the full text of the report (PMID 42660846, DOI 10.3881/j.issn.1000-503X.16881) for comprehensive data.
This article reinforces the importance of pathology in diagnosing rare, EBV-associated splenic neoplasms and aims to increase clinical awareness through a case report and literature-based discussion.